Skip to main content

The absence of Endospanin 1 protein expression protects against harmful alterations associated with obesity 

"A study conducted by the team “Functional Pharmacology and Pathophysiology of Membrane Receptors” suggests that preferentially favoring lipid uptake in adipocytes can limit the alterations associated with obesity induced by a high-fat diet, and promote a "metabolically healthier" obesity. This is dependent on a protein called Endospanin 1, which controls the cellular localization of the lipid transporter CD36. This work is published in the journal JCI Insight."

The study highlights two important concepts: the importance of receptor localization at the cell surface and the notion of “metabolically healthy” obesity. These concepts are linked by a protein called 'Endospanin 1' (also known as Leprot or OBRGRP).

Obesity is a crucial research topic in Europe, addressed by the European Union's research and innovation programs (Horizon Europe). Obesity is a condition that often causes health problems, such as steatosis (accumulation of fat in the liver), type 2 diabetes, and low-grade chronic inflammation, leading to cancers and cardiovascular diseases. However, some individuals with obesity do not necessarily develop metabolic disorders, highlighting the notion of “metabolically healthy obesity”, whose existence is controversial and mechanisms are unclear.

CD36, which has attracted much attention, is a pleiotropic receptor initially described as a lipid-binding receptor and is primarily known for its role in lipid transport in adipose tissue, particularly in fat cells called “adipocytes”. Usually, the overall amount of this protein or its messenger RNA is measured to monitor its function, but its exact localization within the cell is not always taken into account.

The current work reveals that the trafficking protein, Endospanin 1, regulates the amount of CD36 on the surface of fat cells. In the absence of Endospanin 1, levels of CD36 receptor are increased at the surface of adipocytes, which promotes fat absorption by adipocytes and thus prevents the deleterious accumulation of fat in other organs. In line with these observations, mice deleted for Endospanin 1, fed a high-fat diet, develop obesity but with fewer health problems (better glucose tolerance, less fat in the liver, less inflammation, better insulin sensitivity). Interestingly, this correlation has also been observed in humans, suggesting that a low level of Endospanin 1 may help promote “metabolically healthy” obesity in humans.

The study highlights the importance of evaluating the levels of receptors and transmembrane proteins on the surface of cells, a variable often underestimated but which can have significant consequences in pathology. Research on the underlying molecular mechanisms of obesity and its metabolic alterations remains an important area of investigation. It is essential for understanding the disease, developing effective prevention and treatment strategies, improving public health, and reducing the economic and social impacts related to overweight and obesity.

Reference :

Roca-Rivada A, Do Cruzeiro M, Denis RG, Zhang Q, Rouault C, Rouillé Y, Launay JM, Cruciani-Guglielmacci C, Mattot V, Clément K, Jockers R, Dam J. Whole-body deletion of Endospanin 1 protects from obesity-associated deleterious metabolic alterations. JCI Insight. 2024 Apr 2;9(9):e168418. doi: 10.1172/jci.insight.168418.
https://insight.jci.org/articles/view/168418

The study was funded by:

European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 241592 and from the European Union’s Horizon Europe Research and Innovation Program under grant agreement 101080465 (OBELISK project), by the Agence Nationale de la Recherche ANR-12-JSV1-0011, ANR-15-CE14-0025, ANR-21-CE14-0041, Department Hospitalo Universitaire (DHU) AUTHORS, Fondation pour la recherche medicale, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS).

This work was led by Drs Julie DAM / Ralf Jockers Team, INSERM, Institut COCHIN.

Contact : This email address is being protected from spambots. You need JavaScript enabled to view it.

Back to Resources

Read more …The absence of Endospanin 1 protein expression protects against harmful alterations associated...

  • Hits: 97

The absence of Endospanin 1 protein expression protects against harmful alterations associated with obesity 

"A study conducted by the team “Functional Pharmacology and Pathophysiology of Membrane Receptors” suggests that preferentially favouring lipid uptake in adipocytes can limit the alterations associated with obesity induced by a high-fat diet and promote a "metabolically healthier" obesity. This is dependent on a protein called Endospanin 1, which controls the cellular localisation of the lipid transporter CD36. This work is published in the journal JCI Insight." 

The study highlights two important concepts: the importance of receptor localisation at the cell surface and the notion of “metabolically healthy” obesity. These concepts are linked by a protein called 'Endospanin 1' (also known as Leprot or OBRGRP). 

Obesity is a crucial research topic in Europe, addressed by the European Union's research and innovation programs (Horizon Europe). Obesity is a condition that often causes health problems, such as steatosis (accumulation of fat in the liver), type 2 diabetes, and low-grade chronic inflammation, leading to cancers and cardiovascular diseases. However, some individuals with obesity do not necessarily develop metabolic disorders, highlighting the notion of “metabolically healthy obesity”, whose existence is controversial, and mechanisms are unclear. 

CD36, which has attracted much attention, is a pleiotropic receptor initially described as a lipid-binding receptor and is primarily known for its role in lipid transport in adipose tissue, particularly in fat cells called “adipocytes”. Usually, the overall amount of this protein or its messenger RNA is measured to monitor its function, but its exact localisation within the cell is not always taken into account. 

The current work reveals that the trafficking protein, Endospanin 1, regulates the amount of CD36 on the surface of fat cells. In the absence of Endospanin 1, levels of CD36 receptor are increased at the surface of adipocytes, which promotes fat absorption by adipocytes and thus prevents the deleterious accumulation of fat in other organs. In line with these observations, mice deleted for Endospanin 1, fed a high-fat diet, develop obesity but with fewer health problems (better glucose tolerance, less fat in the liver, less inflammation, better insulin sensitivity). Interestingly, this correlation has also been observed in humans, suggesting that a low level of Endospanin 1 may help promote “metabolically healthy” obesity in humans. 

The study highlights the importance of evaluating the levels of receptors and transmembrane proteins on the surface of cells, a variable often underestimated but which can have significant consequences in pathology. Research on the underlying molecular mechanisms of obesity and its metabolic alterations remains an important area of investigation. It is essential for understanding the disease, developing effective prevention and treatment strategies, improving public health, and reducing the economic and social impacts related to overweight and obesity. 

Reference : 

Roca-Rivada A, Do Cruzeiro M, Denis RG, Zhang Q, Rouault C, Rouillé Y, Launay JM, Cruciani-Guglielmacci C, Mattot V, Clément K, Jockers R, Dam J. Whole-body deletion of Endospanin 1 protects from obesity-associated deleterious metabolic alterations. JCI Insight. 2024 Apr 2;9(9):e168418. doi: 10.1172/jci.insight.168418. 

https://insight.jci.org/articles/view/168418 

The study was funded by: 

European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 241592 and from the European Union’s Horizon Europe Research and Innovation Program under grant agreement 101080465 (Obelisk Project), by the Agence Nationale de la Recherche ANR-12-JSV1-0011, ANR-15-CE14-0025, ANR-21-CE14-0041, Department Hospitalo Universitaire (DHU) AUTHORS, Fondation pour la recherche medicale, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS).  

This work was led by Drs Julie DAM / Ralf Jockers Team, INSERM, Institut COCHIN. 

Contact : This email address is being protected from spambots. You need JavaScript enabled to view it. 

  • Hits: 16

EU Policy Corner

The Obelisk Policy Programme

Here you will find details on how the Obelisk project is engaging with policymakers and decision-makers to inform future strategies relating to childhood obesity.  This page also includes useful links to policy-related directories and resources.  As the project develops additional resources and deliverables, such as policy guidelines, will be added to this page.

Policy Workshop

In collaboration with the European Childhood Obesity Group, the Obelisk project will run an annual policy workshop for the length of the project’s duration. The policy workshop will gather national and local health policy representatives and experts in the field of obesity to discuss opportunities and strategies to craft effective policy to combat childhood obesity. This year, the workshop will take place during the ECOG 2024 Congress in Ghent, Belgium, which starts on the 8th of October 2024.

If you are a policymaker and interested in participating in the workshop, you will need to register for the ECOG Congress. Read more about the policy workshop and congress here.

Specialist Policy Panel

The Obelisk project will establish a Specialist Policy Panel with the task of assessing the cost-effectiveness of Obelisk interventions and therapies, which will support the translation of the trial results into novel policies for the prevention of childhood obesity. The panel will include experts in a variety of relevant fields. More information on the panel will follow soon.

Policy Guidelines

The discussions held during the policy workshops and the work of the Specialist Policy Panel throughout the project will serve as the basis for the Obelisk Policy Guidelines, a final set of evidence-based policy recommendations. The guidelines will then be disseminated among relevant stakeholders and policymakers as the final stage of Obelisk’s policy outreach programme.

EU Policy Resources & Directory

Your one-stop directory for relevant policy stakeholders and policy monitoring. 

European Commission

Below are links to access the webpages of the relevant Commission Directorate-Generals and agencies. Here, you will find resources related to their work and initiatives, policy positions, news, and funding opportunities for research projects.

European Parliament

Below are links to the most relevant committees within the EU Parliament working on health-related issues. You will find on these pages a description of their work, activity reports, news, and their meeting calendars. Also included is a general calendar outlining the Parliament's schedule for 2024.

Council of The EU

Below are links to the pages of the two most relevant Council configurations for the Obelisk project: the Environment Council and the Employment, Social Policy, Health and Consumers Council. On these pages, you will find a description of their function, an agenda of their upcoming meetings, and resources relating to their work.

Must-Read Resources

Read more …EU Policy Corner

  • Hits: 973

Advisory Board

Advisory Board

A Scientific Advisory Board (SAB) and an Ethics Advisor will support the Obelisk consortium.

The SAB monitors progress and provides external scientific advice to the consortium to continuously improve the quality and excellence of the project’s research.

The Ethics Advisor ensures that ethical issues are properly addressed and ethical obligations are fulfilled throughout the project.

Name Country Role Organisation

Anke Hinney


Germany

Professor, Head of the Section of Molecular Genetics in Mental Disorders
and Institute of Sex and Gender-Sensitive Medicine
Vice Dean for Young Scientists and Diversity, Medical Faculty of the
University of Duisburg-Essen

University of Duisburg-Essen

Antje Körner


Germany

Professor and Head at Center of Pediatric Research, Leipzig University Children’s Hospital, Leipzig and Head of Childhood Obesity and Metabolic Research

Helmholtz-Institut für Metabolismus-, Adipositas- und Gefäßforschung (HI-MAG)

University Children’s Hospital,
Leipzig

David Meyre


France

University Professor (University of Lorraine) - Hospital Practitioner (Nancy University Hospital) 

Director of the INSERM / University of Lorraine UMR1256 Nutrition-genetics and exposure to environmental risks (NGERE) Research Unit Vandoeuvre les Nancy, France 

University Hospital of Nancy

Name Country Role Organisation

Daniel Vasmant


France

Dr (MD, PhD) Nephrologist, Coordinator at Regional Association of Nephrology of Ile-de-France (RENIF)

(RENIF), Paris

View Project

Read more …Advisory Board

  • Hits: 446

Scientific Publications

Scientific Publications

Publications which have been published by Obelisk partners can be found listed below.  More will be added as the project progresses.

Title Author(s) Date Publication

1471-P: Impaired Delta Opioid Receptor Function Protects against Type 2 Diabetes and Results in Enhanced Insulin Secretion-A Functional Genetic Study


Amélie Bonnefond, Philippe Froguel et al.

14/06/2024

Diabetes (Supplement)

Whole-body deletion of Endospanin 1 protects from obesity-associated deleterious metabolic alterations


Arturo Roca- Rivada, Julie Dam, Ralf Jockers et al.

08/05/2024

JCI Insight

Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes


Lise Folon, Philippe Froguel, Amélie Bonnefond et al.

03/01/2024

Diabetes Care

Novel markers and networks related to restored skeletal muscle transcriptome after bariatric surgery


Meriem Ouni et al.

12/12/2023

Obesity

Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity


Wenwen Gao, Philippe Froguel, Julie Dam, Amélie Bonnefond, Ralf Jockers et al.

05/10/2023

Nature Metabolism

View Research

Read more …Scientific Publications

  • Hits: 1206